Results 101 to 110 of about 21,341,984 (280)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis

, 2018
Masashi Uehara, Yukio Nakamura, Jun Takahashi, Takako Suzuki, Hiroyuki Kato Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan Background: Multiple-system atrophy (MSA) is an α-synucleinopathy with a very ...
Kato H, Suzuki T, Nakamura Y, Uehara M, Takahashi J   +4 more
core  

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers, Yaqiao Wei, Dinesh K. Deelchand, Adam Berrington, Young Woo Park, Guita Banan, Michal Povazan, Jens T. Rosenberg, André J. W. van der Kouwe, Tetsuo Ashizawa, Khalaf O. Bushara, Chiadi U. Onyike, Sub H. Subramony, Jeremy D. Schmahmann, Brian J. Soher, Peter B. Barker, Thomas H. Mareci, Eva‐Maria Ratai, Lynn E. Eberly, Gülin Öz   +19 more
wiley   +1 more source

Multiple System Atrophy

, 2017
Multiple system atrophy is a group of diseases characterized by parkinsonism, ataxia, and dysautonomia. Although the etiology remains unclear, the molecular pathology has been somewhat clarified.
Ejaz A. Shamim, Melvin W. Kong
core   +1 more source

Cognitive and Neuroimaging Divergence Between Juvenile and Adult FUS Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive motor neuron degeneration. Fused in sarcoma (FUS)‐associated juvenile ALS (jALS) represents a distinct and aggressive subgroup with rapid deterioration and poor prognosis.
Alexandra V. Jürs, Marcel Naumann, Annaliis Lehto, Hanna Schön, Jens Kurth, Johannes Prudlo, Andreas Hermann, Elisabeth Kasper   +7 more
wiley   +1 more source

Can a Type-2 Diabetes Mellitus drug be hope for Multiple System Atrophy?

Advances in Clinical Neuroscience & Rehabilitation, 2020
Demir, Yeliz
doaj   +1 more source

A mouse model of adult-onset multiple system atrophy

Neurobiology of Disease, 2019
Multiple system atrophy (MSA) is an adult-onset neurodegenerative disorder clinically characterized by autonomic failure in addition to various combinations of symptoms of parkinsonism, cerebellar ataxia, and pyramidal dysfunction.
Kunikazu Tanji, Yasuo Miki, Fumiaki Mori, Yoshikazu Nikaido, Hidemi Narita, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayashi   +7 more
doaj   +1 more source

Attentional functions in multiple system atrophy and Parkinson's disease

, 1996
Objective-To assess cognitive performances of patients with striatonigral degeneration type multiple system atrophy compared with those of patients with Parkinson's disease.
GASPARINI, Marina, G. Meco, DORICCHI, FABRIZIO   +2 more
core   +1 more source

Digital Cognitive Phenotyping for Differential Diagnosis and Monitoring in Neurological Conditions

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the utility, accessibility, and equivalence to supervised scales of online cognitive assessment in older individuals with cognitive impairment. Methods Patients with Alzheimer's disease (AD, n = 31), idiopathic normal pressure hydrocephalus (iNPH, n = 26), and traumatic brain injury (TBI, n = 23) completed online cognitive ...
Martina Del Giovane, Valentina Giunchiglia, Michael C. B. David, Magdalena A. Kolanko, William R. Trender, Peter J. Hellyer, Harmeena Kaur, David J. Sharp, Christopher Carswell, Paresh A. Malhotra, Adam Hampshire   +10 more
wiley   +1 more source

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis [PDF]

, 2010
Cerebral atrophy is a compound measure of the neurodegenerative component of multiple sclerosis (MS) and a conceivable outcome measure for clinical trials monitoring the effect of neuroprotective agents.
Boden, B.H., Uitdehaag, B. M. J., Barkhof, F., Knol, D.L., Fazekas, F., L. Kappos, F. Barkhof, Sandbrink, R., B. Boden, Pohl, C., Boden, B., Uitdehaag, B.M.J., Filippi, M., D. L. Knol, Dattola, V., Polman, C. H., C. H. Polman, I. J. van den Elskamp, M. Filippi, van den Elskamp, I. J., Filippi, M., Wagner, K., B. M. J. Uitdehaag, Polman, C.H., C. Pohl, Kappos, L., van den Elskamp, I.J., R. Sandbrink, Elskamp, I.J. van den, F. Fazekas, V. Dattola, K. Wagner, Knol, D. L.   +32 more
core   +3 more sources

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source